Clinical applications of cytokines: New directions in the therapy of atopic diseases

Annals of Allergy, Asthma and Immunology

Volumn 79, Issue 1, 1997, Pages 5-16

  Jirapongsananuruk, Orathai ^a   Leung, Donald Y M ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; RECOMBINANT ALPHA INTERFERON; STEM CELL FACTOR; TACROLIMUS; TUMOR NECROSIS FACTOR;

ALLERGIC RHINITIS; ALLERGY; ATOPY; CELLULAR IMMUNITY; EFFECTOR CELL; EOSINOPHIL; HELPER CELL; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; MAST CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0030802862     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63078-5     Document Type: Review

References (122)

1. Kroemer G, Moreno de Alboran I, Gonzalo J, Martins C. Immunoregulation by cytokines. Crit Rev Immunol 1993;13:163-91.
2. Borish L, Rosenwasser L. Update on cytokines. J Allergy Clin Immunol 1996;97:719-34.
3. Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-71.
4. Jones HE, Inouye JC, McGerity JL, Lewis CW. Atopic disease and serum immunoglobulin E. Br J Dermatol 1975;92:17-25.
5. Dolovich J, Hargreave FE, Chalmers R, et al. Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 1973;52:38-46.
6. Charlesworth EN, Hood AF, Soter NA, et al. Cutaneous late-phase response to allergen: mediator release and inflammatory cell infiltration. J Clin Invest 1989;83:1519-26.
7. Solley GO, Gleich GJ, Jordan RE, Schroeter AL. The late phase of the immediate wheal and flare skin reaction: its dependence upon IgE antibodies. J Clin Invest 1976;58: 408-16.
8. Kay AM, Ying S, Varney V, et al. Messenger RNA expression of cytokine gene cluster, interleukin 3 (IL-3), IL-5, and granulocyte/ macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775-8.
9. Cartier A, Thomson N, Frith P, et al. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982;70: 170-7.
10. Warner J, Price J, Soothill J, Hey E. Controlled trial of hyposensitization with Dermatophagoides pteronyssinus antigen in children with asthma. Lancet 1978;2:912-7.
11. Galli S, Gordon J, Wershil B. Cytokine production by mast cells and basophils. Curr Opin Immunol 1991;3: 865-72.
12. Plaut M, Pierce JH, Watson CJ, et al. Mast cell lines produce lymphokines in response to cross-linkage of FcεRI to calcium ionophores. Nature 1989; 229:64-7.
13. Mosmann T. Cytokines and immune regulation. In: Rich RR, FleisherTA, Schwartz BD, Shearer WT, Strober W, eds. Clinical immunology: principle and practice. Missouri: Mosby-Year Book, Inc, 1996:217-30.
14. McKenzie ANJ, Culpepper JA, de Wala Malefyt R, et al. Interleukin-13, a novel cell-derived cytokine that regulates human monocyte and B cell function. Proc Natl Acad Sci USA 1992;90:3735-9.
15. Smith C, Barker J, Lee T. Adhesion molecules in allergic inflammation. Am Rev Respir Dis 1993;148:S75-8.
16. Montefort S, Roche WR, Howart PH, et al. Intercellular adhesion molecule-1 (ICAM-1) and endothelial leukocyte adhesion molecule-1. Eur Respir J 1992;5:815-23.
17. Groves RW, Allen MH, Haskard DO, MacDonald DM. Endothelial leukocyte adhesion molecule-1 in acute and chronic eczema. In: Czernielewski JM, eds. Immunological and pharmacological aspects of atopic and contact eczema. Basel: Karger, 1991:85-8.
18. Kyan-Aung U, Haskard D, Poston R, et al. Endothelial leukocyte adhesion molecule-1 and intercellular adhesion molecule-1 mediate the adhesion of eosinophils to endothelial cell in vitro and are expressed by endothelium in allergic cutaneous inflammation in vivo. J Immunol 1991;146:521-8.
19. Leung D, Pober J, Cotran R. Expression of endothelial-leukocyte adhesion molecule-1 in elicited late phase allergic reactions. J Clin Invest 1991; 87:1805-9.
20. Bittleman D, Casale T. Allergic models and cytokines. Am J Respir Crit Care Med 1994;150:S72-76.
21. Walsh G, Mermod J, Harnell A, et al. Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol 1991; 146:3419-23.
22. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87: 1541-6.
23. Hamid Q, Boguniewicz M, Leung DYM. Differential cytokine gene expression in acute vs chronic atopic dermatitis. J Clin Invest 1994;94: 870-6.
24. Schleimer RP, Ebisawa M, Georas SN, Bochner BS. The role of adhesion molecules and cytokines in eosinophil recruitment. In: Gleich GJ, Kay AB, eds, Eosinophils in allergy and inflammation. New York: Marcel Dekker, Inc, 1993:99-114.
25. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994;15:127-33.
26. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secretory proteins. J Immunol 1986;136:2348-57.
27. H2: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7:145-73.
28. H2 cells. J Clin Immunol 1995; 15:121-9.
29. H2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 1991;146:1169-74.
30. H2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23:1445-9.
31. H2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
32. H2 cells. J Immunol 1992;148:3820-9.
33. Seder RA, Paul WE, Davis MM, de St. Groth BF. The presence of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992;176:1091-8.
34. H1) specific immune responses and inhibits the development of IL-4 producing T cells. J Exp Med 1993;177: 1199-204.
35. Schmitt E, Hoehn P, Huels C, et al. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-β. Eur J Immunol 1994;24:2271-8.
36. H2 murine helper T lymphocyte clones using IL-2 and recombinant IFN-gamma. J Immunol 1989;143:15-22.
37. Heinzel F, Sadick M, Holaday B, et al. Reciprocal expression of interferon-gamma or IL-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-67.
38. Coffman RL, Ohara J, Bond MW, et al. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986;136:4538-41.
39. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
40. H1 clones. J Exp Med 1989;170: 2081-95.
41. Janeway CJ, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-85.
42. Reiser H, Stadecher M. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335: 1369-77.
43. Bluestone J. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555-9.
44. Walunas T, Lenschow D, Bakker C, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
45. Tivol E, Boriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:54-7.
46. Linsley P, Greene J, Brady W. Human B7-1 and BT-2 bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793-801.
47. H2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-18.
48. Freeman G, Bousoiotis V, Anumanthan A, et al. B7-1 and B7-2 do not deliver identical costimulatory signal, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2: 523-32.
49. Jirapongsananuruk O, Hofer MF, Leung DYM. Dysregulation of B7-1 (CD80) and B7-2 (CD86) expression in atopic dermatitis [Abstract]. J Allergy Clin Immunol 1997;99 (part 2): 1077A.
50. Gascan H, Gauchet J-F, Roncarolo M-G, et al. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991;173:747-50.
51. Gauchat J, Gascan H, de Waal Malefeijt R, de Vries J. Regulation of germ-line epsilon switching in clone EBV-transformed and malignant human B cell lines by cytokines and CD4+ T cell. J Immunol 1992;148: 2291-9.
52. Del Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for IgE synthesis induced in vitro by human T cells clones and their supernatants. J Immunol 1988;140:4193-8.
53. Jabara H, Fu S, Geha R, Vercelli D. CD40 and IgE synergism between anti-CD40 monoclonal antibody and interleukin-4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990;172:1861-4.
54. Thyphronitis G, Tsokos GC, June CH, et al. IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon-γ. Proc Natl Acad Sci USA 1989; 86:5580-4.
55. Wu CY, Sarfati M, Heusser C, et al. Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes. J Clin Invest 1991;87:870-7.
56. Linsley P, Clark E, Ledbetter J. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990;87:5031-5.
57. Life P, Aubry JP, Estoppey S, Schnuriger V, Bonnefoy JY. CD28 functions as an adhesion molecule and is involved in the regulation of human IgE synthesis. Eur J Immunol 1995;25:333-9.
58. Vercelli D, Jabara HH, Arai K, et al. Endogenous IL-6 plays an obligatory role in IL-4 induced human IgE synthesis. Eur J Immunol 1989;19: 1419-25.
59. Pène J, Rousset F, Brière F, et al. Interleukin-5 enhances interleukin-4 induced IgE production by normal human B cells: The role of soluble CD23 antigen. Eur J Immunol 1989; 18:929-35.
60. de Vries J. Novel fundamental approaches to intervening in IgE-mediated allergic diseases. J Invest Dermatol 1994;102:141-4.
61. Leung DYM. Mechanisms of the human allergic response: clinical implications. Pediatr Clin N Am 1994;41: 727-43.
62. Coffman R, Carty J. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 1986;136: 949-54.
63. Leung DYM. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995;96:302-18.
64. Reinhold U, Pawelec G, Wehrmann W, et al. Immunoglobulin E and immunoglobulin G subclass distribution in vivo and relationship to in vitro generation of interferon-gamma and neopterin in patients with severe atopic dermatitis. Int Arch Allergy Appl Immunol 1988;87:120-6.
65. Kiniwa M, Gately M, Gubler U, et al. Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1992; 90:262-6.
66. Jones SM, Sampson HA. The role of allergens in atopic dermatitis. In: Leung DYM, ed. Atopic dermatitis: from pathogenesis to treatment. Austin: RG Landes Co, 1996:41-66.
67. Chan SC, Kim JW, Henderson WR, et al. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 1993; 151:3345-52.
68. Lester MR, Gately M, Trumble A, Leung DYM. Effects of IL-12 and staphylococcal toxic shock syndrome toxin-1 on the interferon-gamma response in atopic dermatitis. J Immunol 1995;95:913-8.
69. Matsumoto K, Schleimer RP, Saito H, et al. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995; 86:1437-43.
70. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1996; 267:1506-10.
71. Yang E, Zha J, Jocket J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
72. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375:78-81.
73. Bratton DL, Hamid Q, Boguniewicz M, et al. Granulocyte macrophage-colony stimulating factor inhibition of monocyte apoptosis contributes to the chronic monocyte activation in atopic dermatitis. J Clin Invest 1995; 95:211-8.
74. Suzuki S, Okubo M, Kaise S, et al. Gold sodium thiomalate selectivity inhibits interleukin-5-mediated eosinophil survival. J Allergy Clin Immunol 1995;96:251-6.
75. Woolley KL, Gibson PG, Carty K, et al. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 1996;154:237-43.
76. Nimmagadda SE, Spahn JD, Surs W, et al. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Cell Mol Biol 1997;155:87-93.
77. Clayton MH, Leung DYM, Surs W, Szefler SJ. Altered glucocorticoid receptor binding in atopic dermatitis. J Allergy Clin Immunol 1995;96: 421-3.
78. Herrscher RF, Kasper C, Sullivan TJ. Endogenous cortisol regulates immunoglobulin E-dependent late phase reaction. J Clin Invest 1992;90: 596-603.
79. Secrist H, Chelen CJ, Wen Y, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
80. Schleimer RP, Beck L, Schweibert L, et al. Inhibition of inflammatory cell recruitment by glucocorticoids: cytokines as primary targets. In: Schleimer RP, Busse WW, O'Byrne P, eds. Topical glucocorticoids in asthma: mechanisms and clinical actions. New York: Marcel Dekker, Inc, 1997:203-38.
81. Spann JD, Leung DYM, Szefler SJ. Difficult to control asthma: new insights and implications for management. In: Szefler SJ, Leung DYM, eds. Severe asthma: pathogenesis and management. New York: Marcel Dekker, Inc, 1996:497-536.
82. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136-42.
83. Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807-15.
84. Mori A, Suko M, Nishizaki Y, et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994;104:32-5.
85. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990;70:323-9.
86. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin A in corticosteroid-dependent chronic severe asthma. Lancet 1992;339:324-8.
87. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, cross-over study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
88. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991;71:452-4.
89. Kino T, Hatanaka H, Hashimoto M, et al. FK-506. a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, physico-chemical and biological characteristics. J Antibiot 1987;40: 1249-55.
90. Nagakawa H. Tacrolimus ointment for atopic dermatitis [Letter]. Lancet 1994;344:883.
91. Boguniewicz M, Leung DYM, et al. Treatment of pediatric atopic dermatitis (AD) with tacrolimus ointment [Abstract]. J Allergy Clin Immunol 1997;99 (Part 2):1939A.
92. Finkelman FD, Katona IM, Urban JF, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988;141:2335-41.
93. Finkelman F, Villacreses N, Holmes J. Role of antigen-specific T cell help in the generation of in vivo antibody responses. II. Sustained antigen-specific T cell help is required to induce a specific antibody response. J Immunol 1992;149:3845-50.
94. Maliszewski C, Sato T, Vanden Bos T, et al. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. J Immunol 1990;144:3028-33.
95. Sato T, Widmer M, Finkelman F, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993; 150:2717-23.
96. Fanslow W, Clifford K, Park L, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991;147:535-40.
97. Nasert S, Millner M, Herz U, et al. Therapeutic interference with interferon-gamma (IFN-γ) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt 1995:118-30.
98. Van Oosterhout A, Ladenius A, Savelkoul H, et al. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 1993;147:548-52.
99. Eum S, Haile S, Lefort J, et al. Eosinophil recruitment into the respiratory epithelium following antigenic challenge in hyper-IgE mice is accompanied by interleukin 5-dependent bronchial hyperresponsiveness. Proc Natl Acad Sci USA 1995;92:12290-4.
100. Lukacs NW, Strieter RM, Schaklu CL, et al. Macrophage inflammatory protein-1α influences eosinophil recruitment in antigen-specific airway inflammation. Eur J Immunol 1995; 25:245-51.
101. Sim T, Hilsmeier K, Reece L, et al. Interleukin-1 receptor antagonist protein inhibits the synthesis of IgE and proinflammatory cytokines by allergen-stimulated mononuclear cells. Am J Respir Cell Mol Biol 1994;11: 473-7.
102. Okada S, Inoue H, Yamauchi K, et al. Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol 1995;95:1236-45.
103. Aversa G, Punnonen J, Cocks BJ, et al. An IL-4 mutant protein inhibits both IL-4 and IL-13-induced human IgG4 and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993;178: 2213-8.
104. Heinzel F, Schoenhaut D, Rerko R, et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
105. Kiniwa M, Gately M, Gubler U, et al. Recombinant IL-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1992;90:262-6.
106. H2 cytokine expression in mice. J Exp Med 1995; 182:1527-36.
107. Torrelo A, Harto A, Sendagorta E, et al. Interferon-alpha therapy in atopic dermatitis. Acta Derm Venereol 1992;72:370-2.
108. Paukkonen K, Fraki J, Horsmanheimo M. Interferon-alpha treatment decreases the number of blood eosinophils in patients with severe atopic dermatitis. Acta Derm Venereol 1993;73:141-2.
109. Gruschwitz MS, Peters KP, Heese A, et al. Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema. Int Arch Allergy Immunol 1993;101:20-30.
110. Pung YH, Vetro SW, Bellanti JA. Use of interferons in atopic (IgE-mediated) diseases. Ann Allergy 1993;71:234-8.
111. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa. J Allergy Clin Immunol 1994; 94:1318-26.
112. Hanifin JM, Schneider LC, Leung DYM, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-97.
113. Boguniewicz M, Jaffe HS, Izu A, et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990;88:365-70.
114. Reinhold U, Kukel S, Brzoska J, Kreysel H. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993;29:58-63.
115. Li JT, Yunginger JW, Reed CE, et al. Lack of suppression of IgE production by recombinant interferon gamma: a controlled trial in patients with allergic rhinitis. J Allergy Clin Immunol 1990;85:934-40.
116. Boguniewicz M, Schneider LC, Milgrom H, et al. Treatment of steroid-dependent asthma with recombinant interferon-gamma. Clin Exp Allergy 1993;23:785-90.
117. Jaffe HA, Buhl R, Mastrangeli A, et al. Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-γ to the human lung. J Clin Invest 1991;88:297-302.
118. Lack G, Renz H, Saloga J, et al. Nebulized but not parenteral IFN-γ decreases IgE production and normalizes airways function in a murine model of allergen sensitization. J Immunol 1994;152:2546-54.
119. Lack G, Bradley KL, Hamelmann E, et al. Nebulized IFN-γ inhibits the development of secondary allergic responses in mice. J Immunol 1996; 157:1432-9.
120. Martin R, Boguniewicz M, Henson J, et al. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis 1993;148:1677-82.
121. Boguniewicz M, Martin RJ, Martin D, et al. The effects of nebulized recombinant interferon gamma in asthmatic airways. J Allergy Clin Immunol 1995;95:133-5.
122. Renz H, Enssle K, Lauffer L, et al. Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. Int Arch Allergy Immunol 1995;106:46-54.